Risk Patterns of Subsequent Primary Cancers following Esophagectomy in Early-Stage Thoracic Esophageal Squamous Cell Cancer Patients

2015 ◽  
Vol 101 (3) ◽  
pp. 328-333 ◽  
Author(s):  
Wen-Si Hu ◽  
Zeng-Jun Liu ◽  
Jian-Bo Zhang ◽  
Zeng-Liang Wang ◽  
Ning Yang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Early Stage ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer

scholarly journals Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yu-Chieh Ho ◽  
Yuan-Chun Lai ◽  
Hsuan-Yu Lin ◽  
Ming-Hui Ko ◽  
Sheng-Hung Wang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Performance Status ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
Lymphocyte Ratio ◽  
Cardiac Dose

AbstractWe aimed to determine the prognostic significance of cardiac dose and hematological immunity parameters in esophageal cancer patients after concurrent chemoradiotherapy (CCRT). During 2010–2015, we identified 101 newly diagnosed esophageal squamous cell cancer patients who had completed definitive CCRT. Patients' clinical, dosimetric, and hematological data, including absolute neutrophil count, absolute lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR), at baseline, during, and post-CCRT were analyzed. Cox proportional hazards were calculated to identify potential risk factors for overall survival (OS). Median OS was 13 months (95% confidence interval [CI]: 10.38–15.63). Univariate analysis revealed that male sex, poor performance status, advanced nodal stage, higher percentage of heart receiving 10 Gy (heart V10), and higher NLR (baseline and follow-up) were significantly associated with worse OS. In multivariate analysis, performance status (ECOG 0 & 1 vs. 2; hazard ratio [HR] 3.12, 95% CI 1.30–7.48), heart V10 (> 84% vs. ≤ 84%; HR 2.24, 95% CI 1.26–3.95), baseline NLR (> 3.56 vs. ≤ 3.56; HR 2.36, 95% CI 1.39–4.00), and follow-up NLR (> 7.4 vs. ≤ 7.4; HR 1.95, 95% CI 1.12–3.41) correlated with worse OS. Volume of low cardiac dose and NLR (baseline and follow-up) were associated with worse patient survival.

scholarly journals Implications for the Ajcc Staging Systems on Esophageal Squamous Cell Cancer Patients Receiving Multimodality Therapy

2014 ◽  
Vol 25 ◽  
pp. v63
Author(s):  
Motoo Nomura ◽  
Tetsuya Abe ◽  
Hiroya Taniguchi ◽  
Shigenori Kadowaki ◽  
Daisuke Takahari ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Multimodality Therapy ◽  
Esophageal Squamous Cell Cancer ◽  
Staging Systems ◽  
Ajcc Staging

scholarly journals Microvessel density as a prognostic factor in esophageal squamous cell cancer patients

Medicine ◽  
2017 ◽  
Vol 96 (29) ◽  
pp. e7600 ◽  
Author(s):  
Guangzhi Ma ◽  
Jing Zhang ◽  
Hai Jiang ◽  
Nannan Zhang ◽  
Yunjie Zhu ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Microvessel Density ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer

scholarly journals Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer

2021 ◽  
Author(s):  
Binhao Huang ◽  
Maria Christine Xu ◽  
Arjun Pennathur ◽  
Zhigang Li ◽  
Zhiguo Liu ◽  
...  
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Squamous Cell ◽  
Adjuvant Treatment ◽  
Squamous Cell Cancer ◽  
Early Stage ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
R0 Resection ◽  
Muscularis Mucosa

Abstract Objective To evaluate the outcome following the strategy of endoscopic R0 resection (ER) plus adjuvant treatment (AT) versus esophagectomy for esophageal squamous cell cancer in T1a invading muscularis mucosa (M3)-T1b stage. Methods We evaluated the outcomes of 46 esophageal squamous cell cancer (ESCC) patients with T1aM3-T1b stage who underwent ER + AT from the Esophageal Cancer Endoscopic Therapy Consortium (ECETC) and compared these outcomes to 92 patients who underwent esophagectomy. Propensity score matching (1:2) was used, with overall survival (OS) and relapse-free survival (RFS) being compared between the two groups. Results During a median follow-up of 32 months, there were no statistical differences (P = 0.226) in OS between the two groups. The 1-, 2-, and 3-year overall survival in the esophagectomy group was 95%, 91%, and 84%, respectively. There were no mortalities within three years in the ER + AT group. The RFS between the two groups was also not significantly different (P = 0.938). The 1-, 2-, and 3-year RFS of patients in the esophagectomy group was 90%, 90%, and 83%, respectively, while it was 97%, 94%, and 74% in the ER + AT group, respectively. The local recurrence rates between the two groups were not significantly different (P = 0.277). Conclusions This first multicenter analysis showed similar outcomes were found regarding OS and RFS between the two groups in T1aM3-T1b stage patients. ER + AT may be considered in high-risk patients or for those who refuse esophagectomy.

Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer: a retrospective study

2019 ◽  
Author(s):  
Min Liu ◽  
Qingqing Jia ◽  
Xiaolin Wang ◽  
Changjiang Sun ◽  
Jianqi Yang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Objective Response ◽  
Progression Free Survival ◽  
Optimal Dose ◽  
Esophageal Squamous Cell Cancer ◽  
Grade 3

Abstract Background: The optimal chemotherapy regimen for refractory esophageal squamous cell cancer patients is uncertain. Our retrospective study assessed the efficacy and safety of irinotecan plus raltitrexed in esophageal squamous cell cancer patients who were previously treated with multiple systemic therapies. Methods: Between January 2016 and December 2018, records of 38 esophageal squamous cell cancer patients who underwent irinotecan plus raltitrexed chemotherapy after at least one line of chemotherapy were reviewed. Efficacy assessment was performed every two cycles according to the RECIST version 1.1. Results: A total of 95 cycles of chemotherapy were administered, and the median course was 3 (range 2–6). There was no treatment-related death. Nine patients had partial response, 21 had stable disease and 8 had progressive disease. The overall objective response rate was 23.68% (9/38) and the disease control rate was78.94% (30/38). After a median follow-up of 18.5 months, the median progression-free survival and overall survival were 105 days and 221 days respectively. There were 5 patients (13.15%) with grade 3/4 leukopenia, 3 patients (7.89%) with grade 3/4 neutropenia and 1 patient (2.63%) with grade 3/4 diarrhea. Conclusions: The combination of irinotecan plus raltitrexed was effective for pretreated esophageal squamous cell cancer patients. Further studies are needed to determine the optimal dose of the two drugs.

Sign in / Sign up

Export Citation Format

Share Document